Adjunctive therapy in parkinson's disease: The role of rasagiline

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 285-294

  Gaines, Kathryn D ^a   Hinson, Vanessa K ^b  

^a Advanced Healthcare   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Clinical trials; Parkinson's disease; Rasagiline; Treatment

Indexed keywords

AMANTADINE; CIMETIDINE; CIPROFLOXACIN; CYCLOBENZAPRINE; DEXTROMETHORPHAN; DEXTROPROPOXYPHENE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; FLUVOXAMINE; HYPERICUM PERFORATUM EXTRACT; LEVODOPA; LONG ACTING DRUG; METHADONE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; OMEPRAZOLE; PETHIDINE; PLACEBO; RASAGILINE; SELEGILINE; TOCOPHEROL; TRAMADOL; TRIHEXYPHENIDYL; TYRAMINE;

ABNORMAL DREAMING; ACCIDENTAL INJURY; ADJUVANT THERAPY; ANOREXIA; ANXIETY; AORTA ANEURYSM; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BACKACHE; BALANCE IMPAIRMENT; CLINICAL FEATURE; COGNITION; CONFUSION; CONSTIPATION; DEPRESSION; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; DYSKINESIA; HALLUCINATION; HEART ATRIUM FLUTTER; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; INSOMNIA; MONOTHERAPY; MUSCULOSKELETAL PAIN; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOGENESIS; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PSYCHOSIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; SEROTONIN SYNDROME; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYMPTOM; SYNCOPE; THORAX PAIN; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84930482013     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S25142     Document Type: Review

References (99)

1. Oberdorf J, Schmidt P. Improving care for people with Parkinson's disease. National Parkinson Foundation. Feb 2010. Available from: http://www.parkinson.org/ NationalParkinsonFoundation/fles/c2/c2abb799-4e2b-41c5-8c06-47-f3424a58d0.pdf. Accessed February 6, 2012.
2. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223-236.
3. Haas LF. Jean Martin Charcot (1825-1893) and Jean Baptiste Charcot (1867-1936). J Neurol Neurosurg Psychiatry. 2001;71(4):524.
4. Siderowf A, Stern M. Update on Parkinson disease. Ann Intern Med. 2003;138(8):651-658.
5. Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):968-975.
6. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
7. Zesiewicz T, Hauser R. Medical treatment of motor and non motor features of Parkinson's disease. Continuum. 2007;13(1):12-38.
8. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards of Subcommittee of the American Academy of Neurology. Continuum. 2007;13(1):193-201.
9. Braak H, Bohl J, Muller C, et al. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord. 2006;21(12):2042-2051.
10. Forno LS. Concentric hyaline intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc. 1969;17(6):557-575.
11. Ishiyama M, Yagishita S, Hasegawa K, Yokoyama T. Ultrastructural study (transmission and scanning EM) of cortical Lewy bodies. Neuropatholog y. 2006;26(2):A58.
12. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211.
13. Kincses ZT, Vecsei L. Pharmacological therapy in Parkinson's disease: focus on neuroprotection. CNS Neurosci Ther. 2011;17(5):345-367.
14. Bogaerts V, Theuns J, van Broeckhoven C. Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? Genes Brain Behav. 2008;7(2):129-151.
15. Maker HS, Weiss C, Silides DJ, Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem. 1981;36(2):589-593.
16. Gerlach M, Riederer P, Przuntek H, Youdim MB. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol. 1991;208(4):273-286.
17. Langston J W, Ballard P, Tetrud J W, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219(4587):979-980.
18. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglias are positive for HLA-DR in the sub stantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38(8):1285-1291.
19. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol (Berl). 2003;106(6):518-526.
20. Mirza B, Hadberg H, Thomsen P, Moos T. The absence of reactive astro-cytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience. 2000;95(2):425-432.
21. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett. 1996; 211(1):13-16.
22. Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T. Interleukin-2 but not basic fbroblast growth factor is elevated in parkinsonian brain. Short communication. J Neural Transm. 1996;103(8-9):1077-1081.
23. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fuid in Parkinson's disease. Neurosci Lett. 1995;193(2):129-132.
24. Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T. Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1995;9(1): 87-92.
25. Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994;180(2):147-150.
26. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fuid from parkinsonian patients. Neurosci Lett. 1994;165(1-2):208-210.
27. Mogi M, Harada M, Kojima K, et al. Beta 2-microglobulin decrease in cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1989;104(1-2):241-246.
28. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis. 2006;21(2):404-412.
29. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 2005; 57(2):168-175.
30. Chau KY, Ching HL, Schapira AH, Cooper JM. Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J Neurochem. 2009;110(3):1005-1013.
31. Olanow C W, Prusiner SB. Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A. 2009;106(31):12571-12572.
32. Bonci A, Grillner P, Mercuri NB, Bernardi G. L-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dop-aminergic neurons. J Neurosci. 1998;18(17):6693-6703.
33. Ping HX, Shepard PD. Apamin-sensitive Ca(2+)-activated K+ channels regulate pacemaker activity in nigral dopamine neurons. Neuroreport. 1996;7(3):809-814.
34. Rodriguez MC, Obeso JA, Olanow C W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol. 1998;44(3 Suppl 1):S175-S188.
35. Dingledine R, Borges K, Bowie D, Traynelis S F. The glutamate receptor ion channels. Pharmacol Rev. 1999;51(1):7-61.
36. Greenamyre JT, Porter RH. Anatomy and physiology of glutamate in the CNS. Neurology. 1994;44(11 Suppl 88):S7-S13.
37. Hetz CA. ER stress signaling and the BCL-2 family of proteins: from adaptation to irreversible cellular damage. Antioxid Redox Signal. 2007;9(12):2345-2355.
38. Lindholm D, Wootz H, Korhonen L. ER stress and neurodegenerative diseases. Cell Death Differ. 2006;13(3):385-392.
39. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332-1343.
40. Kerr J F, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239-257.
41. Hirsch EC, Hunot S. Neuroinfammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382-397.
42. Ferrer I, Blanco R, Cutillas B, Ambrosio S. Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Neuropathol Appl Neurobiol. 2000;26(5):424-433.
43. Huot P, Parent A. Dopaminergic neurons intrinsic to the striatum. J Neurochem. 2007;101(6):1441-1447.
44. Kitahama K, Geffard M, Araneda S, et al. Localization of L-DOPA uptake and decarboxylating neuronal structures in the cat brain using dopamine immunohistochemistry. Brain Res. 2007;1167: 56-70.
45. Yamada H, Aimi Y, Nagatsu I, Taki K, Kudo M, Arai R. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Neurosci Res. 2007;59(1):1-7.
46. Fahn S; and the Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol. 2005;252 Suppl 4: IV37-IV42.
47. Rajput AH, Uitti R, Rajput A, et al. Timely levodopa (LD) administration prolongs survival in Parkinson's disease. Parkinsonism Relat Disord. 1997;3(3):159-165.
48. Zesiewicz T, Sullivan K, Hauser R. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology and treatment. Curr Neurol Neurosci Rep. 2007;7(4):302-310.
49. Dostert PL, Strolin Benedetti M, Tipton KF. Interactions of monoamine oxidase with substrates and inhibitors. Med Res Rev. 1989;9(1):45-89.
50. Birkmayer W, Riederer P, Youdim MBH, Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenyl. J Neural Trans. 1975;36(3-4):303-326.
51. Kalir A, Sabbagh A, Youdim MBH. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol. 1981;73(1):55-64.
52. Sandler M, Glover V, Ashford A, Stern GM. Absence of "cheese effect" during deprenyl therapy: some recent studies. J Neural Trans. 1978;43(3-4):209-215.
53. Elsworth JD, Glover V, Reynolds G P, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology. 1978;57(1):33-38.
54. Lees AJ, Kohout LJ, Shaw KM, et al. Deprenyl in Parkinson's disease. Lancet. 1997;310 (8042):791-795.
55. Parkinson Study Group. DATATOP: a multi center controlled clinical trial in early Parkinson's disease. Arch Neurol. 1989;46(10):1052-1060.
56. LeWitt PA. Neuroprotection by anti-oxidant strategies in Parkinson's disease. Eur Neurol. 1993;33 Suppl 1:24-30.
57. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. 1998. Ann Neurol. 44(3 Suppl 1):S160-S166.
58. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet. 1997;33(2):91-102.
59. Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 1997; 25(6):657-662.
60. Bar Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004;355(3):169-172.
61. Binda C, Hubalek F, Li M, et al. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem. 2004;47(7):1767-1774.
62. Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev. 1999;111(2-3):189-200.
63. Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neuroprotective factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005;19(13):1899-1901.
64. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol. 2001;63(1):71-124.
65. Wang L, Muramatsu S, Lu Y, et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther. 2002;9(6):381-389.
66. Mandel S, Weinreb O, Amit T, Youdim MB. Mechanism of neuropro-tective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev. 2005;48(2):379-387.
67. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdim MB, Naoi M. Neuroprotection by propargylamines in Parkinson's disease: s uppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002;24(5):675-682.
68. Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 2000;67(5):577-585.
69. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R) salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem. 2002;82(4):913-923.
70. Youdim MB, Amit T, Falach-Yogev M, Bar Am O, Maruyama W, Naoi M. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti- Parkinson drug, rasagiline. Biochem Pharmacol. 2003;66(8):1635-1641.
71. Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehy-drogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem. 2001;78(4):727-735.
72. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MB. Neuro-protection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004;18(12):1471-1473.
73. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000;23(6):324-330.
74. Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord. 2004;19(8):916-923.
75. Freedman NM, Mishani E, Krausz Y, et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med. 2005;46(10):1618-1624.
76. Kupsch A, Sautter J, Gotz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm. 2001;108(8-9):985-1009.
77. Heikkila RE, Duvoisin RC, Finberg J P, Youdim MB. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol. 1985;116(3):313-317.
78. Olanow C W, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-1278.
79. Hurley D. FDA committee: Rasagiline rejected as 'disease modifying' for Parkinson Disease. 2011;11(21):1, 6-7.
80. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937-1943.
81. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561-566.
82. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-2508.
83. Hauser R, Lew M, Hurtig H, Ondo W, Wojcieszek J. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease: P251. Mov Disord. 2005;20:S75.
84. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol. 1996;40(1):99-107.
85. Shults C W, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-1550.
86. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fuctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial. Lancet. 2005;365(9463):947-954.
87. Parkinson Study Group. A randomized placebo-controlled trial of rasa-giline in levodopa-treated patients with Parkinson disease and motor fuctuations: the PRESTO study. Arch Neurol. 2005;62(2):241-248.
88. Montastruc JL, Chaumerliac C, Desboeuf K, et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol. 2000;23(5):271-275.
89. Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol. 2004;143(3):371-378.
90. Goetz CG, Schwid S, Eberly S, et al. Safety of rasagiline in elderly patients with Parkinson disease. Neurology. 2006;66:1427-1429.
91. Da Prada M, Zurcher G, Wuthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988;26:31-56.
92. Parkinson Study Group. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO Study). Neurology. 2001; 56 Suppl 3:A345.
93. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet. 1991;337(8735):246.
94. Chen JJ, Ly AV. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm. 2006;63(10):915-928.
95. Azilect.com [homepage on the Internet]. Anti-depressant chart review. Teva Neuroscience, Inc; 2010. Available from: http://www.azilect. com/HCP/Tools-Resources/Anti-Depressant-Fact-Card.aspx. Accessed February 13, 2012.
96. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol. 2005;45(8):878-894.
97. Azilect.com [homepage on the Internet]. Azilect dosage: Parkinson's disease medication dosing. Teva Neuroscience; 2010. Available from: http://www.azilect.com/HCP/Azilect-Therapy/Dosing.aspx. Accessed February 13, 2012.
98. Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multi center study. Mov Disord. 2011;26(10):1851-1858.
99. Hudry J, Rinne JO, Keranen T, Eckert L, Cochran JM. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. Ann Pharmacother. 2006;40(4):651-657.